Preclinical	O
fibrinolysis	B:C0016017
in	O
patients	O
with	O
ST	O
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
in	O
a	O
rural	O
region	O
.	O

Preclinical	O
fibrinolysis	O
in	O
patients	O
with	O
ST	B:C1536220
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
in	O
a	O
rural	O
region	O
.	O

In	O
the	O
current	B:C4291682
guidelines	I:C4291682
for	O
the	O
treatment	O
of	O
patients	O
with	O
ST	O
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
(	O
ST	O
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
)	O
,	O
the	O
European	O
Society	O
of	O
Cardiology	O
(	O
ESC	O
)	O
recommends	O
preclinical	O
fibrinolysis	O
as	O
a	O
reperfusion	O
therapy	I:C0035124
if	O
,	O
due	O
to	O
long	O
transportation	O
times	O
,	O
no	O
cardiac	O
catheterisation	I:C0018795
is	O
available	O
within	O
90	O
-	O
120	O
min	O
.	O

In	O
the	O
current	O
guidelines	I:C4291682
for	O
the	O
treatment	B:C0087111
of	O
patients	O
with	O
ST	O
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
(	O
ST	O
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
)	O
,	O
the	O
European	O
Society	O
of	O
Cardiology	O
(	O
ESC	O
)	O
recommends	O
preclinical	O
fibrinolysis	O
as	O
a	O
reperfusion	O
therapy	I:C0035124
if	O
,	O
due	O
to	O
long	O
transportation	O
times	O
,	O
no	O
cardiac	O
catheterisation	I:C0018795
is	O
available	O
within	O
90	O
-	O
120	O
min	O
.	O

In	O
the	O
current	O
guidelines	I:C4291682
for	O
the	O
treatment	O
of	O
patients	O
with	O
ST	B:C1536220
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
(	O
ST	O
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
)	O
,	O
the	O
European	O
Society	O
of	O
Cardiology	O
(	O
ESC	O
)	O
recommends	O
preclinical	O
fibrinolysis	O
as	O
a	O
reperfusion	O
therapy	I:C0035124
if	O
,	O
due	O
to	O
long	O
transportation	O
times	O
,	O
no	O
cardiac	O
catheterisation	I:C0018795
is	O
available	O
within	O
90	O
-	O
120	O
min	O
.	O

In	O
the	O
current	O
guidelines	I:C4291682
for	O
the	O
treatment	O
of	O
patients	O
with	O
ST	O
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
(	O
ST	B:C1536220
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
)	O
,	O
the	O
European	O
Society	O
of	O
Cardiology	O
(	O
ESC	O
)	O
recommends	O
preclinical	O
fibrinolysis	O
as	O
a	O
reperfusion	O
therapy	I:C0035124
if	O
,	O
due	O
to	O
long	O
transportation	O
times	O
,	O
no	O
cardiac	O
catheterisation	I:C0018795
is	O
available	O
within	O
90	O
-	O
120	O
min	O
.	O

In	O
the	O
current	O
guidelines	I:C4291682
for	O
the	O
treatment	O
of	O
patients	O
with	O
ST	O
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
(	O
ST	O
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
)	O
,	O
the	O
European	O
Society	O
of	O
Cardiology	O
(	O
ESC	O
)	O
recommends	O
preclinical	O
fibrinolysis	B:C0016017
as	O
a	O
reperfusion	O
therapy	I:C0035124
if	O
,	O
due	O
to	O
long	O
transportation	O
times	O
,	O
no	O
cardiac	O
catheterisation	I:C0018795
is	O
available	O
within	O
90	O
-	O
120	O
min	O
.	O

In	O
the	O
current	O
guidelines	I:C4291682
for	O
the	O
treatment	O
of	O
patients	O
with	O
ST	O
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
(	O
ST	O
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
)	O
,	O
the	O
European	O
Society	O
of	O
Cardiology	O
(	O
ESC	O
)	O
recommends	O
preclinical	O
fibrinolysis	O
as	O
a	O
reperfusion	B:C0035124
therapy	I:C0035124
if	O
,	O
due	O
to	O
long	O
transportation	O
times	O
,	O
no	O
cardiac	O
catheterisation	I:C0018795
is	O
available	O
within	O
90	O
-	O
120	O
min	O
.	O

In	O
the	O
current	O
guidelines	I:C4291682
for	O
the	O
treatment	O
of	O
patients	O
with	O
ST	O
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
(	O
ST	O
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
)	O
,	O
the	O
European	O
Society	O
of	O
Cardiology	O
(	O
ESC	O
)	O
recommends	O
preclinical	O
fibrinolysis	O
as	O
a	O
reperfusion	O
therapy	I:C0035124
if	O
,	O
due	O
to	O
long	O
transportation	O
times	O
,	O
no	O
cardiac	B:C0018795
catheterisation	I:C0018795
is	O
available	O
within	O
90	O
-	O
120	O
min	O
.	O

However	O
,	O
there	O
is	O
little	O
remaining	O
in	O
-	O
depth	O
expertise	O
in	O
this	O
method	O
because	O
fibrinolysis	B:C0016017
is	O
presently	O
only	O
rarely	O
indicated	O
.	O

However	O
,	O
there	O
is	O
little	O
remaining	O
in	O
-	O
depth	O
expertise	O
in	O
this	O
method	O
because	O
fibrinolysis	O
is	O
presently	O
only	O
rarely	O
indicated	B:C1444656
.	O

In	O
a	O
rural	O
area	O
in	O
southwestern	B:C1710136
Germany	O
,	O
where	O
an	O
emergency	O
primary	I:C1532297
percutaneous	I:C1532297
coronary	I:C1532297
intervention	I:C1532297
was	O
not	O
routinely	O
available	O
within	O
90	O
-	O
120	O
min	O
,	O
156	O
ST	O
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
patients	O
underwent	O
fibrinolysis	O
with	O
the	O
plasminogen	O
activator	I:C0256103
reteplase	I:C0256103
,	O
performed	O
by	O
trained	O
emergency	O
physicians	O
.	O

In	O
a	O
rural	O
area	O
in	O
southwestern	O
Germany	B:C0017480
,	O
where	O
an	O
emergency	O
primary	I:C1532297
percutaneous	I:C1532297
coronary	I:C1532297
intervention	I:C1532297
was	O
not	O
routinely	O
available	O
within	O
90	O
-	O
120	O
min	O
,	O
156	O
ST	O
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
patients	O
underwent	O
fibrinolysis	O
with	O
the	O
plasminogen	O
activator	I:C0256103
reteplase	I:C0256103
,	O
performed	O
by	O
trained	O
emergency	O
physicians	O
.	O

In	O
a	O
rural	O
area	O
in	O
southwestern	O
Germany	O
,	O
where	O
an	O
emergency	B:C1532297
primary	I:C1532297
percutaneous	I:C1532297
coronary	I:C1532297
intervention	I:C1532297
was	O
not	O
routinely	O
available	O
within	O
90	O
-	O
120	O
min	O
,	O
156	O
ST	O
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
patients	O
underwent	O
fibrinolysis	O
with	O
the	O
plasminogen	O
activator	I:C0256103
reteplase	I:C0256103
,	O
performed	O
by	O
trained	O
emergency	O
physicians	O
.	O

In	O
a	O
rural	O
area	O
in	O
southwestern	O
Germany	O
,	O
where	O
an	O
emergency	O
primary	I:C1532297
percutaneous	I:C1532297
coronary	I:C1532297
intervention	I:C1532297
was	O
not	O
routinely	O
available	O
within	O
90	O
-	O
120	O
min	O
,	O
156	O
ST	B:C1536220
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
patients	O
underwent	O
fibrinolysis	O
with	O
the	O
plasminogen	O
activator	I:C0256103
reteplase	I:C0256103
,	O
performed	O
by	O
trained	O
emergency	O
physicians	O
.	O

In	O
a	O
rural	O
area	O
in	O
southwestern	O
Germany	O
,	O
where	O
an	O
emergency	O
primary	I:C1532297
percutaneous	I:C1532297
coronary	I:C1532297
intervention	I:C1532297
was	O
not	O
routinely	O
available	O
within	O
90	O
-	O
120	O
min	O
,	O
156	O
ST	O
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
patients	O
underwent	O
fibrinolysis	B:C0016017
with	O
the	O
plasminogen	O
activator	I:C0256103
reteplase	I:C0256103
,	O
performed	O
by	O
trained	O
emergency	O
physicians	O
.	O

In	O
a	O
rural	O
area	O
in	O
southwestern	O
Germany	O
,	O
where	O
an	O
emergency	O
primary	I:C1532297
percutaneous	I:C1532297
coronary	I:C1532297
intervention	I:C1532297
was	O
not	O
routinely	O
available	O
within	O
90	O
-	O
120	O
min	O
,	O
156	O
ST	O
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
patients	O
underwent	O
fibrinolysis	O
with	O
the	O
plasminogen	B:C0256103
activator	I:C0256103
reteplase	I:C0256103
,	O
performed	O
by	O
trained	O
emergency	O
physicians	O
.	O

In	O
a	O
rural	O
area	O
in	O
southwestern	O
Germany	O
,	O
where	O
an	O
emergency	O
primary	I:C1532297
percutaneous	I:C1532297
coronary	I:C1532297
intervention	I:C1532297
was	O
not	O
routinely	O
available	O
within	O
90	O
-	O
120	O
min	O
,	O
156	O
ST	O
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
patients	O
underwent	O
fibrinolysis	O
with	O
the	O
plasminogen	O
activator	I:C0256103
reteplase	I:C0256103
,	O
performed	O
by	O
trained	O
emergency	O
physicians	B:C0031831
.	O

The	O
practicality	O
of	O
the	O
treatment	B:C0087111
,	O
as	O
well	O
as	O
complications	O
and	O
the	O
mortality	O
of	O
the	O
patients	O
in	O
the	O
preclinical	O
phase	O
until	O
arrival	O
at	O
the	O
hospital	O
,	O
were	O
retrospectively	O
studied	I:C0035363
.	O

The	O
practicality	O
of	O
the	O
treatment	O
,	O
as	O
well	O
as	O
complications	B:C0009566
and	O
the	O
mortality	O
of	O
the	O
patients	O
in	O
the	O
preclinical	O
phase	O
until	O
arrival	O
at	O
the	O
hospital	O
,	O
were	O
retrospectively	O
studied	I:C0035363
.	O

The	O
practicality	O
of	O
the	O
treatment	O
,	O
as	O
well	O
as	O
complications	O
and	O
the	O
mortality	O
of	O
the	O
patients	O
in	O
the	O
preclinical	O
phase	O
until	O
arrival	O
at	O
the	O
hospital	B:C0019994
,	O
were	O
retrospectively	O
studied	I:C0035363
.	O

The	O
practicality	O
of	O
the	O
treatment	O
,	O
as	O
well	O
as	O
complications	O
and	O
the	O
mortality	O
of	O
the	O
patients	O
in	O
the	O
preclinical	O
phase	O
until	O
arrival	O
at	O
the	O
hospital	O
,	O
were	O
retrospectively	B:C0035363
studied	I:C0035363
.	O

The	O
mean	O
time	O
from	O
onset	O
of	O
the	O
symptoms	B:C1457887
to	O
first	O
medical	O
contact	I:C0582446
was	O
114	O
±	O
116	O
min	O
.	O

The	O
mean	O
time	O
from	O
onset	O
of	O
the	O
symptoms	O
to	O
first	O
medical	B:C0582446
contact	I:C0582446
was	O
114	O
±	O
116	O
min	O
.	O

The	O
mean	O
interval	O
to	O
the	O
start	O
of	O
fibrinolysis	B:C0016017
of	O
13.5	O
±	O
6.4	O
min	O
was	O
within	O
the	O
30	O
min	O
mandated	O
by	O
the	O
ESC	O
.	O

The	O
mean	O
interval	O
to	O
the	O
start	O
of	O
fibrinolysis	O
of	O
13.5	O
±	O
6.4	O
min	O
was	O
within	O
the	O
30	O
min	O
mandated	B:C0520248
by	O
the	O
ESC	O
.	O

Patients	O
with	O
inferior	B:C2882099
STEMI	I:C2882099
represented	O
the	O
largest	O
subgroup	O
.	O

Patients	O
with	O
inferior	O
STEMI	I:C2882099
represented	O
the	O
largest	O
subgroup	B:C1515021
.	O

Occurring	O
in	O
39	O
cases	O
(	O
25	O
%	O
)	O
,	O
complications	B:C0009566
due	O
to	O
infarction	O
were	O
relatively	O
common	O
during	O
the	O
prehospital	O
phase	O
,	O
including	O
15	O
cases	O
(	O
9.6	O
%	O
)	O
of	O
cardiogenic	O
shock	I:C0036980
,	O
but	O
in	O
all	O
cases	O
the	O
complications	O
were	O
manageable	O
.	O

Occurring	O
in	O
39	O
cases	O
(	O
25	O
%	O
)	O
,	O
complications	O
due	O
to	O
infarction	B:C0021308
were	O
relatively	O
common	O
during	O
the	O
prehospital	O
phase	O
,	O
including	O
15	O
cases	O
(	O
9.6	O
%	O
)	O
of	O
cardiogenic	O
shock	I:C0036980
,	O
but	O
in	O
all	O
cases	O
the	O
complications	O
were	O
manageable	O
.	O

Occurring	O
in	O
39	O
cases	O
(	O
25	O
%	O
)	O
,	O
complications	O
due	O
to	O
infarction	O
were	O
relatively	O
common	O
during	O
the	O
prehospital	B:C2735050
phase	O
,	O
including	O
15	O
cases	O
(	O
9.6	O
%	O
)	O
of	O
cardiogenic	O
shock	I:C0036980
,	O
but	O
in	O
all	O
cases	O
the	O
complications	O
were	O
manageable	O
.	O

Occurring	O
in	O
39	O
cases	O
(	O
25	O
%	O
)	O
,	O
complications	O
due	O
to	O
infarction	O
were	O
relatively	O
common	O
during	O
the	O
prehospital	O
phase	O
,	O
including	O
15	O
cases	O
(	O
9.6	O
%	O
)	O
of	O
cardiogenic	B:C0036980
shock	I:C0036980
,	O
but	O
in	O
all	O
cases	O
the	O
complications	O
were	O
manageable	O
.	O

Occurring	O
in	O
39	O
cases	O
(	O
25	O
%	O
)	O
,	O
complications	O
due	O
to	O
infarction	O
were	O
relatively	O
common	O
during	O
the	O
prehospital	O
phase	O
,	O
including	O
15	O
cases	O
(	O
9.6	O
%	O
)	O
of	O
cardiogenic	O
shock	I:C0036980
,	O
but	O
in	O
all	O
cases	O
the	O
complications	B:C0009566
were	O
manageable	O
.	O

Occurring	O
in	O
39	O
cases	O
(	O
25	O
%	O
)	O
,	O
complications	O
due	O
to	O
infarction	O
were	O
relatively	O
common	O
during	O
the	O
prehospital	O
phase	O
,	O
including	O
15	O
cases	O
(	O
9.6	O
%	O
)	O
of	O
cardiogenic	O
shock	I:C0036980
,	O
but	O
in	O
all	O
cases	O
the	O
complications	O
were	O
manageable	B:C0243095
.	O

No	O
patient	O
died	B:C1306577
before	O
arrival	O
at	O
the	O
hospital	O
.	O

No	O
patient	O
died	O
before	O
arrival	O
at	O
the	O
hospital	B:C0019994
.	O

As	O
lysis	B:C0024348
-	O
associated	O
adverse	O
effects	I:C0879626
,	O
merely	O
two	O
uncomplicated	O
mucosal	O
haemorrhages	I:C0854375
and	O
one	O
case	O
of	O
mild	O
allergic	I:C0863090
skin	I:C0863090
reactions	I:C0863090
were	O
seen	O
.	O

As	O
lysis	O
-	O
associated	O
adverse	B:C0879626
effects	I:C0879626
,	O
merely	O
two	O
uncomplicated	O
mucosal	O
haemorrhages	I:C0854375
and	O
one	O
case	O
of	O
mild	O
allergic	I:C0863090
skin	I:C0863090
reactions	I:C0863090
were	O
seen	O
.	O

As	O
lysis	O
-	O
associated	O
adverse	O
effects	I:C0879626
,	O
merely	O
two	O
uncomplicated	O
mucosal	B:C0854375
haemorrhages	I:C0854375
and	O
one	O
case	O
of	O
mild	O
allergic	I:C0863090
skin	I:C0863090
reactions	I:C0863090
were	O
seen	O
.	O

As	O
lysis	O
-	O
associated	O
adverse	O
effects	I:C0879626
,	O
merely	O
two	O
uncomplicated	O
mucosal	O
haemorrhages	I:C0854375
and	O
one	O
case	O
of	O
mild	B:C0863090
allergic	I:C0863090
skin	I:C0863090
reactions	I:C0863090
were	O
seen	O
.	O

In	O
emergency	O
situations	O
with	O
long	O
transportation	O
times	O
to	O
the	O
nearest	O
suitable	O
cardiac	B:C0018795
catheterisation	I:C0018795
laboratory	O
,	O
preclinical	O
fibrinolysis	O
in	O
ST	O
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
still	O
represents	O
a	O
workable	O
method	O
.	O

In	O
emergency	O
situations	O
with	O
long	O
transportation	O
times	O
to	O
the	O
nearest	O
suitable	O
cardiac	O
catheterisation	I:C0018795
laboratory	B:C0022877
,	O
preclinical	O
fibrinolysis	O
in	O
ST	O
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
still	O
represents	O
a	O
workable	O
method	O
.	O

In	O
emergency	O
situations	O
with	O
long	O
transportation	O
times	O
to	O
the	O
nearest	O
suitable	O
cardiac	O
catheterisation	I:C0018795
laboratory	O
,	O
preclinical	O
fibrinolysis	B:C0016017
in	O
ST	O
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
still	O
represents	O
a	O
workable	O
method	O
.	O

In	O
emergency	O
situations	O
with	O
long	O
transportation	O
times	O
to	O
the	O
nearest	O
suitable	O
cardiac	O
catheterisation	I:C0018795
laboratory	O
,	O
preclinical	O
fibrinolysis	O
in	O
ST	B:C1536220
-	I:C1536220
segment	I:C1536220
elevation	I:C1536220
myocardial	I:C1536220
infarction	I:C1536220
still	O
represents	O
a	O
workable	O
method	O
.	O

Success	O
of	O
this	O
strategy	O
requires	O
particularly	O
strong	O
training	O
of	O
the	O
emergency	O
physicians	B:C0031831
in	O
ECG	O
and	O
lysis	O
therapy	O
,	O
and	O
co-operation	O
with	O
nearby	O
cardiac	O
centres	I:C0475309
.	O

Success	O
of	O
this	O
strategy	O
requires	O
particularly	O
strong	O
training	O
of	O
the	O
emergency	O
physicians	O
in	O
ECG	B:C1623258
and	O
lysis	O
therapy	O
,	O
and	O
co-operation	O
with	O
nearby	O
cardiac	O
centres	I:C0475309
.	O

Success	O
of	O
this	O
strategy	O
requires	O
particularly	O
strong	O
training	O
of	O
the	O
emergency	O
physicians	O
in	O
ECG	O
and	O
lysis	B:C0024348
therapy	O
,	O
and	O
co-operation	O
with	O
nearby	O
cardiac	O
centres	I:C0475309
.	O

Success	O
of	O
this	O
strategy	O
requires	O
particularly	O
strong	O
training	O
of	O
the	O
emergency	O
physicians	O
in	O
ECG	O
and	O
lysis	O
therapy	B:C0087111
,	O
and	O
co-operation	O
with	O
nearby	O
cardiac	O
centres	I:C0475309
.	O

Success	O
of	O
this	O
strategy	O
requires	O
particularly	O
strong	O
training	O
of	O
the	O
emergency	O
physicians	O
in	O
ECG	O
and	O
lysis	O
therapy	O
,	O
and	O
co-operation	O
with	O
nearby	O
cardiac	B:C0475309
centres	I:C0475309
.	O

